Furthermore, decreased cerebral blood flow and glucose metabolism, along with increased cerebrovascular resistance, have been observed in both human AD cases and transgenic mouse models overexpressing amyloid precursor protein, as well as in high-risk populations for AD carrying the apolipoprotein E4 allele (Korte et al., 2020). This evidence concerns the gene APP and Alzheimer disease.